Skip to main content

Treosulfan FDA Approval Status

FDA Approved: No
Generic name: treosulfan
Company: Medexus Pharmaceuticals Inc.
Treatment for: Stem Cell Transplant Conditioning

Treosulfan is a bifunctional alkylating agent in development for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Development timeline for treosulfan

Jul 25, 2022Treosulfan NDA Resubmitted to FDA
Aug  3, 2021Complete Response Letter Received from FDA for Treosulfan

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.